Canada· CA-DIN-02466236
RYDAPT
A midostaurin product containing midostaurin, registered in Canada by NOVARTIS PHARMACEUTICALS CANADA INC. The same ATC class is registered in 12 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Midostaurin is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EX10 (midostaurin), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Midostaurin · ATC L01EX10
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- MIDOSTAURIN
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Country
- Canada (CA)
- ATC code
- L01EX10
- ATC class
- Midostaurin
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
582 interactions on record for midostaurin.
Graded by severity as the source publishes them — 132 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Midostaurin · interactions on record
582 records
- 132 severe
- 445 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Midostaurin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomRydapt 25mg capsulesNovartis Pharmaceuticals UK Ltd
- NetherlandsRydapt 25 mg, zachte capsuleNovartis Europharm Limited
- FinlandRydaptOrifarm Oy
- CzechiaRYDAPTNovartis Europharm Limited, Dublin
- SwitzerlandRydapt 25 mg, WeichkapselnNovartis Pharma Schweiz AG
- United StatesRYDAPTNovartis Pharmaceuticals Corporation
- BelgiumRydapt 25 mgNovartis Europharm
- IcelandRydaptNovartis Europharm Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rydapt
- Liechtenstein · Rydapt
- Norway · Rydapt
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6f1d5241-54f9-453c-b3fc-5f93a4988774 GET /v1/drugs/6f1d5241-54f9-453c-b3fc-5f93a4988774?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02466236",
"form": "CAPSULE",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01EX10",
"schedule": [
"Prescription"
],
"drug_code": "95454",
"strengths": [
"25 MG"
],
"ahfs_class": null,
"substances": [
"MIDOSTAURIN"
],
"product_categorization": null
}See everything about midostaurin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.